Compare HERE & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HERE | ACET |
|---|---|---|
| Founded | 2019 | 1947 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.6M | 83.3M |
| IPO Year | 2022 | 2017 |
| Metric | HERE | ACET |
|---|---|---|
| Price | $1.67 | $6.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | 23.8K | ★ 143.5K |
| Earning Date | 06-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.29 | N/A |
| P/E Ratio | $2.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.46 |
| 52 Week High | $5.80 | $9.97 |
| Indicator | HERE | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 32.40 | 33.56 |
| Support Level | $1.67 | $6.74 |
| Resistance Level | $1.94 | $8.93 |
| Average True Range (ATR) | 0.07 | 0.75 |
| MACD | -0.02 | -0.20 |
| Stochastic Oscillator | 14.62 | 12.22 |
Here Group Ltd is dedicated to creating collectible pop toys that evoke joy and emotional resonance. The group design and compelling storytelling, which provide users with a collecting experience that blends artistic value with emotional warmth, continuously convey a joyful and immersive brand culture. Adhering to the brand philosophy of joy, integrity, wonder, and co-creation, the company is building a vibrant ecosystem connecting creativity and emotion, working hand-in-hand with overall toy enthusiasts to create, share, and transmit dreams.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).